Biotech | December 24, 2021
Lecanemab granted Fast Track designation by the U.S. FDA
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
The capsules are the generic version of the reference listed drug Mycobutin
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Subscribe To Our Newsletter & Stay Updated
